JP2019528774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528774A5 JP2019528774A5 JP2019518451A JP2019518451A JP2019528774A5 JP 2019528774 A5 JP2019528774 A5 JP 2019528774A5 JP 2019518451 A JP2019518451 A JP 2019518451A JP 2019518451 A JP2019518451 A JP 2019518451A JP 2019528774 A5 JP2019528774 A5 JP 2019528774A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cell
- transposon
- acid sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 75
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 54
- 210000001519 tissue Anatomy 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 36
- 208000035475 disorder Diseases 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 102000008579 Transposases Human genes 0.000 claims description 30
- 108010020764 Transposases Proteins 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 230000001939 inductive effect Effects 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 238000002659 cell therapy Methods 0.000 claims description 20
- 102000011727 Caspases Human genes 0.000 claims description 18
- 108010076667 Caspases Proteins 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 15
- 239000000411 inducer Substances 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 230000001988 toxicity Effects 0.000 claims description 10
- 231100000419 toxicity Toxicity 0.000 claims description 10
- 102000004039 Caspase-9 Human genes 0.000 claims description 9
- 108090000566 Caspase-9 Proteins 0.000 claims description 9
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 claims description 9
- 240000007019 Oxalis corniculata Species 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 108010083359 Antigen Receptors Proteins 0.000 claims description 6
- 102000006306 Antigen Receptors Human genes 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 3
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 3
- 238000011467 adoptive cell therapy Methods 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000001736 capillary Anatomy 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 239000002539 nanocarrier Substances 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 210000003038 endothelium Anatomy 0.000 claims description 2
- 230000008622 extracellular signaling Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000003016 hypothalamus Anatomy 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 210000004020 intracellular membrane Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000000578 peripheral nerve Anatomy 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 210000000626 ureter Anatomy 0.000 claims 2
- 102100021238 Dynamin-2 Human genes 0.000 claims 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 108010045758 lysosomal proteins Proteins 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 108010042634 F2A4-K-NS peptide Proteins 0.000 description 4
- 101800001494 Protease 2A Proteins 0.000 description 4
- 101800001066 Protein 2A Proteins 0.000 description 4
- 108700010039 chimeric receptor Proteins 0.000 description 4
- 102200157658 rs1555229948 Human genes 0.000 description 4
- 102220236765 rs80358547 Human genes 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102200015453 rs121912293 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405184P | 2016-10-06 | 2016-10-06 | |
| US62/405,184 | 2016-10-06 | ||
| PCT/US2017/055661 WO2018068022A1 (en) | 2016-10-06 | 2017-10-06 | Inducible caspases and methods for use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528774A JP2019528774A (ja) | 2019-10-17 |
| JP2019528774A5 true JP2019528774A5 (cg-RX-API-DMAC7.html) | 2020-10-08 |
| JP7054694B2 JP7054694B2 (ja) | 2022-04-14 |
Family
ID=60190939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518451A Active JP7054694B2 (ja) | 2016-10-06 | 2017-10-06 | 誘導性カスパーゼおよび使用方法 |
Country Status (18)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3523325B1 (en) | 2016-10-06 | 2025-08-06 | Poseida Therapeutics, Inc. | Inducible caspases and methods for use |
| WO2020037142A1 (en) | 2018-08-17 | 2020-02-20 | Yale University | Compositions and methods for high-throughput activation screening to boost t cell effector function |
| US20220042038A1 (en) | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| JP2022547866A (ja) | 2019-09-05 | 2022-11-16 | ポセイダ セラピューティクス，インコーポレイティド | 同種異系細胞組成物と使用方法 |
| KR20220117915A (ko) | 2019-12-20 | 2022-08-24 | 포세이다 테라퓨틱스, 인크. | 항-muc1 조성물 및 사용 방법 |
| US20230121433A1 (en) | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| US20240060090A1 (en) | 2021-02-23 | 2024-02-22 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
| CA3233506A1 (en) | 2021-10-04 | 2023-04-13 | Joseph S. LUCAS | Transposon compositions and methods of use thereof |
| CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
| CN114736306B (zh) * | 2022-03-01 | 2024-04-19 | 中国科学院深圳先进技术研究院 | 一种受化学调控的蛋白酶工具及其配套底物 |
| US20250228940A1 (en) * | 2022-03-11 | 2025-07-17 | Yale University | Compositions and methods for efficient and stable genetic modification of eukaryotic cells |
| CN118185901B (zh) * | 2022-12-12 | 2025-03-21 | 北京精缮生物科技有限责任公司 | 一种PBase蛋白、融合蛋白、核酸和基因整合系统及应用 |
| IL322767A (en) | 2023-02-21 | 2025-10-01 | Poseida Therapeutics Inc | Genome editing vehicles and methods |
| EP4669746A1 (en) | 2023-02-21 | 2025-12-31 | Poseida Therapeutics, Inc. | COMPOSITIONS AND GENOMIC EDITING PROCESSES |
| CN121195065A (zh) | 2023-04-05 | 2025-12-23 | 波西达治疗公司 | 转座酶多核苷酸及其用途 |
| AU2024317892A1 (en) * | 2023-07-29 | 2025-08-28 | Limited Liability Company «Genetic Technologies» (Llc «Genetic Technologies») | Adeno-associated virus-based expression vectors |
| WO2025038655A1 (en) | 2023-08-14 | 2025-02-20 | Ponce Therapeutics, Inc. | Multimerizer pharmaceutical compositions of rimiducid |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
| US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
| US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
| US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6835394B1 (en) | 1999-12-14 | 2004-12-28 | The Trustees Of The University Of Pennsylvania | Polymersomes and related encapsulating membranes |
| MXPA04002103A (es) | 2001-09-04 | 2004-06-07 | Yeda Res & Dev | Una proteina de union a caspasa-8, su preparacion y uso. |
| WO2006133398A2 (en) | 2005-06-08 | 2006-12-14 | Invitrogen Corporation | In vitro activated donor t-cells to promote transplant engraftment |
| JP4563491B1 (ja) | 2009-07-07 | 2010-10-13 | 株式会社片岡製作所 | レーザ加工機 |
| US8808748B2 (en) | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| US9089520B2 (en) * | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2661275B1 (en) | 2011-01-07 | 2019-01-02 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of high-affinity oxygen binding agents to tumors |
| JP6467406B2 (ja) | 2013-06-05 | 2019-02-13 | ベリカム ファーマシューティカルズ， インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| AU2015226960A1 (en) | 2014-03-07 | 2016-09-15 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| EP3177713B1 (en) | 2014-08-08 | 2020-08-05 | Poseida Therapeutics, Inc. | Compositions and their use for inducing nanoparticle-mediated microvascular embolization of tumors |
| WO2016090111A1 (en) | 2014-12-05 | 2016-06-09 | Vindico NanoBio Technology Inc. | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| US20170000743A1 (en) | 2015-07-02 | 2017-01-05 | Vindico NanoBio Technology Inc. | Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles |
| US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
| US9834743B2 (en) | 2016-04-23 | 2017-12-05 | Seid Mehdi Naeini | Removing pets urin, odor and mildew out of hand made rugs |
| ES2865481T3 (es) | 2016-04-29 | 2021-10-15 | Poseida Therapeutics Inc | Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos |
| EP3523325B1 (en) | 2016-10-06 | 2025-08-06 | Poseida Therapeutics, Inc. | Inducible caspases and methods for use |
-
2017
- 2017-10-06 EP EP17791508.9A patent/EP3523325B1/en active Active
- 2017-10-06 PT PT177915089T patent/PT3523325T/pt unknown
- 2017-10-06 AU AU2017339511A patent/AU2017339511B2/en active Active
- 2017-10-06 CN CN201780075452.8A patent/CN110267980A/zh active Pending
- 2017-10-06 LT LTEPPCT/US2017/055661T patent/LT3523325T/lt unknown
- 2017-10-06 ES ES17791508T patent/ES3051391T3/es active Active
- 2017-10-06 WO PCT/US2017/055661 patent/WO2018068022A1/en not_active Ceased
- 2017-10-06 EP EP25188286.6A patent/EP4640273A2/en active Pending
- 2017-10-06 RU RU2019113152A patent/RU2757058C2/ru active
- 2017-10-06 FI FIEP17791508.9T patent/FI3523325T3/fi active
- 2017-10-06 RS RS20251125A patent/RS67390B1/sr unknown
- 2017-10-06 IL IL265664A patent/IL265664B2/en unknown
- 2017-10-06 JP JP2019518451A patent/JP7054694B2/ja active Active
- 2017-10-06 KR KR1020197012858A patent/KR102447083B1/ko active Active
- 2017-10-06 US US16/339,710 patent/US11377480B2/en active Active
- 2017-10-06 HR HRP20251387TT patent/HRP20251387T1/hr unknown
- 2017-10-06 MX MX2019003983A patent/MX2019003983A/es unknown
- 2017-10-06 DK DK17791508.9T patent/DK3523325T3/da active
- 2017-10-06 BR BR112019006865-1A patent/BR112019006865A2/pt unknown
-
2022
- 2022-06-02 US US17/830,773 patent/US11718656B2/en active Active
-
2023
- 2023-06-13 US US18/333,904 patent/US12358966B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528774A5 (cg-RX-API-DMAC7.html) | ||
| RU2019113152A (ru) | Индуцируемые каспазы и способы использования | |
| Hacker et al. | Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: current status and future perspectives | |
| Spano et al. | Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer | |
| Samaranch et al. | Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates | |
| Rocca et al. | rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study | |
| JP2020048571A5 (cg-RX-API-DMAC7.html) | ||
| Ye et al. | Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration | |
| Gernoux et al. | Muscle-directed delivery of an AAV1 vector leads to capsid-specific T cell exhaustion in nonhuman primates and humans | |
| Petrovic et al. | TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo | |
| Uceda-Castro et al. | Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis | |
| KR20180102172A (ko) | 다논병 및 다른 자가포식 장애의 치료 방법 | |
| JP6750782B2 (ja) | 移植用幹細胞及びその製造方法 | |
| Pyun et al. | Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia | |
| Devaney et al. | Clinical review: gene-based therapies for ALI/ARDS: where are we now? | |
| Baliga et al. | Pulmonary gene delivery—Realities and possibilities | |
| Liu et al. | A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer | |
| Westhaus et al. | Assessment of pre-clinical liver models based on their ability to predict the liver-tropism of adeno-associated virus vectors | |
| WO2002036078A2 (en) | Targeting pluripotent stem cells to tissues | |
| Chauhan et al. | AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice | |
| Zhang et al. | Therapeutic effects of mesenchymal stem cells loaded with oncolytic adenovirus carrying decorin on a breast cancer lung metastatic mouse model | |
| Pichavant et al. | Expression of dog microdystrophin in mouse and dog muscles by gene therapy | |
| US20180117282A1 (en) | Spinal subpial gene delivery system | |
| Park et al. | Therapeutic potential of AAV-FL-Klotho in obesity: Impact on weight loss and lipid metabolism in mice | |
| Bao et al. | Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by TNFR gene transfection |